Q-omics provides the consensus-scored TRIML2 profile across patient tissues and cancer cell-line models. TRIML2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TRIML2 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, TRIML2 RNA expression shows 12,569 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, and TGCT as cancer lineages where TRIML2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIML2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIML2 survival associations across molecular data types. TRIML2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIML2 RNA expression–survival associations across cancer types. High TRIML2 expression shows unfavorable associations in HNSC, KIRC, UVM, BLCA, LUAD and MESO. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TRIML2 RNA expression.
This table summarizes TRIML2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TRIML2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIML2 shows lower tumor expression in COAD and higher tumor expression in HNSC, LUSC, KIRC, BRCA and CHOL. The HNSC box plot shows higher TRIML2 RNA expression in tumor versus normal tissue (log2 FC = +0.760, t-test p < 0.001).
This table shows molecular features associated with TRIML2 in patient tissues and cancer cell lines. In patient samples, TRIML2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIML2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and STOMACH.
